Stock Market Watch

Three Stocks under $5 in the Spotlight Today: LEI, ROYL, and POZN!

by ·




Shares of Lucas Energy, Inc. (AMEX:LEI) are surging with the news of closing an agreement to acquire properties in Wilson, Gonzales, and Karnes Counties for $22 Million! LEI has traded as high as $2.24 and last traded at $2.10 for a gain of 13.51% from yesterday’s close… Get my next ALERT 100% FREE

LEI is an independent oil and gas company, today announced the closing of its previously reported purchase and sale agreement with Nordic Oil USA 1, LP, whereby the Company purchased all of Nordic 1′s right, title and interest in certain oil, gas, and mineral leases located in Wilson, Gonzales and Karnes Counties, Texas, effective July 1, 2011. The property interests acquired represent all of Nordic 1′s interests in the LEI 2009 II and III Capital Programs.

The Company paid $22 million to Nordic 1 in the form of non-recourse, senior secured promissory note in connection with the acquisition, the payment of which was secured only by the properties acquired. The note is due one year from the official closing date (November 18, 2012), bears interest at 6% per annum, and allows early repayments without penalty.


William A. Sawyer, President and Chief Executive Officer of the Company said, “We are very pleased with the acquisition of Nordic 1′s interests which provides LEI with an increase in revenues, proved reserves, and Eagle Ford acreage.” (Read more)

Royale Energy, Inc. (NASDAQ:ROYL) has traded as high as $4.7299 during today’s trading session and last traded at $4.59 for a gain of 18.91% on the day!

ROYL has made two more natural gas discoveries in its core area. The Royale Jewel has been drilled to its total depth. The well is in close proximity to Royale’s production facilities and will begin selling gas in two weeks. Three separate Forbes sands were encountered and the deepest zone has been completed with a stabilized production rate of 3,000,000 cubic ft. of natural gas per day.  Last year the company began producing its Goddard wells 3/4′s of a mile to the north. The Goddard wells have already produced over 2 billion cubic ft. of natural gas to date.

The Royale Bristol was drilled to a total depth of 6,800 ft. and found 40 ft. of Forbes filled natural gas sands. Production casing has been set and the well has a bottom hole shut in pressure of 2,200 psi. The company has also continued its workover program by recompleting another existing well.   The Parks well is now producing from a shallower zone at a stabilized rate of 190,000 cubic ft. per day.

These new discoveries are a confirmation of the significance of Royale’s recently approved new 3D seismic survey. The company will be shooting a 25 square mile 3D seismic survey to expand its prospect and production area to the northwest. They are also a very positive step in the company’s continuing success of replacing and growing its natural gas reserves.

Pozen Inc. (NASDAQ:POZN) has traded as high as $3.72 during today’s trading session and last traded at a share price of $3.52 for a stellar gain of 40.8%!

POZN is a pharmaceutical company committed to transforming medicine that transforms lives, announced today that John R. Plachetka, Pharm.D., the Company’s Chairman, President and Chief Executive Officer, will present at the Piper Jaffray 23rd Annual Healthcare Conference on Wednesday, November 30, 2011 at 2:30 p.m. (ET), at The New York Palace Hotel. Dr. Plachetka’s presentation will be webcast and available for replay on POZEN’s home page at www.pozen.com.

POZN is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years – something almost no other small pharmaceutical company has done. Funded by these two milestone/royalty streams, POZEN is now creating a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

More Posts by this author

Post Written By: Oliver Crowne

Oliver Crowne is the main editor for http://www.StockPreacher.com


Ed Liston

Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing.

You may also like...